An anonymous reader quotes a report from CNBC: Theranos CEO Elizabeth Holmes Monday outlined the steps she will take to increase transparency regarding the efficacy of the company's testing methods. Speaking at the conference of the American Association for Clinical Chemistry, Holmes said that Theranos will partner with other institutions "to validate and publish our results." And Holmes' planned presentation includes research conducted under Institutional Review Board-approved protocols. The company also said it intends to submit its results to a publication for peer-review. Holmes' presentation includes a slate of new products such as its miniLab, a robot that can process samples that normally require manual processing in traditional protocols. Theranos seems to be going back to the research and development drawing board, focusing on these new products instead of its much-debated small-volume blood collection technology. Theranos' miniLab is a self-contained laboratory that allows a robot to run a number of tests on samples. The miniLab contains different modules that allow it to conduct a series of tasks that traditionally would require multiple, separate machines. Theranos used its miniLab to run its Zika nucleic acid-amplification-based assay using finger-prick samples the company collected, some in the Dominican Republic. The samples were shipped back to Palo Alto, California, for analysis. Holmes said the results "demonstrate the miniLab's ability to perform automated, integrated molecular testing comparable to methods that require highly-trained personnel."
Attend or create a Slashdot 20th anniversary party! DEAL: For $25 - Add A Second Phone Number To Your Smartphone for life! Use promo code SLASHDOT25. Check out the new SourceForge HTML5 Internet speed test. ×